生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | BAZ2A and BAZ2B are bromodomain-containing proteins that constitute the central scaffolding protein of the nucleolar remodeling complex (NoRC). GSK2801 is a potent, selective, cell-active inhibitor of BAZ2A and BAZ2B bromodomains. It binds to the BAZ2 bromodomains of BAZ2A and BAZ2B with KD values of 257 and 136nM, respectively. GSK2801 at a concentration of 10μM led to a temperature shift of 4.1 and 2.7°C for BAZ2A and BAZ2B, respectively. An isothermal titration calorimetry binding experiment showed that GSK2801 bound to TAF1L(2) with a binding enthalpy change ΔH of −8.6(±0.02)kcal/mol and a KD value of 3.2μM. A chemoproteomic competition binding assay showed that GSK2801 bound to endogenous BAZ2 proteins with a pKd value of 5.5. In male CD1 mice, GSK2801 exhibited reasonable in vivo exposure, modest clearance, and reasonable plasma stability after an oral dosing of 30mg/kg (Tmax=1.0h; Cmax=435ng/mL; Terminal t1/2=1.5h)[2]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.69mL 0.54mL 0.27mL |
13.46mL 2.69mL 1.35mL |
26.92mL 5.38mL 2.69mL |
参考文献 |
---|